期刊
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
卷 7, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fcimb.2017.00059
关键词
Pseudomonas aeruginosa; lysozyme; treatment regimen; airway infection; multi-drug resistance
资金
- National Research Foundation (NRF) of Korea - Korean government [2014R1A2A2A01002861, 2014R1A4A1008625, 2014R1A1A2059520]
- Korea Healthcare Technology R&D Project of the Ministry for Health, Welfare, and Family Affairs [HI15C0694]
- National Research Foundation of Korea [2014R1A1A2059520, 2014R1A4A1008625, 2014R1A2A2A01002861] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Pseudomonas aeruginosa is capable of establishing airway infections. Human airway mucus contains a large amount of lysozyme, which hydrolyzes bacterial cell walls. P. aeruginosa, however, is known to be resistant to lysozyme. Here, we performed a genetic screen using a mutant library of PAO1, a prototype P. aeruginosa strain, and identified two mutants (Delta bamB and Delta fabY) that exhibited decrease in survival after lysozyme treatment. The bamB and fabY genes encode an outer membrane assembly protein and a fatty acid synthesis enzyme, respectively. These two mutants displayed retarded growth in the airway mucus secretion (AMS). In addition, these mutants exhibited reduced virulence and compromised survival fitness in two different in vivo infection models. The mutants also showed susceptibility to several antibiotics. Especially, Delta bamB mutant was very sensitive to vancomycin, ampicillin, and ceftazidime that target cell wall synthesis. The 1 fabY displayed compromised membrane integrity. In conclusion, this study uncovered a common aspect of two different P. aeruginosa mutants with pleiotropic phenotypes, and suggests that BamB and FabY could be novel potential drug targets for the treatment of P. aeruginosa infection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据